Short answer
Solventum (SOLV) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $2.1B (up 0.7% year over year) with net income of $1.3B.
Q3 2025 key financials · XBRL
- Revenue
- $2.1B
- +0.7% YoY · −3.0% QoQ
- Net income
- $1.3B
- +937.7% YoY · +1306.7% QoQ
- Operating margin
- 80.6%
- Gross margin
- 54.2%
- EPS (diluted)
- $7.23
- +932.9% YoY · +1290.4% QoQ
Source: XBRL data from the Solventum (SOLV) Q3 2025 10-Q on SEC EDGAR. USD.
Solventum Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Total revenue $2,096M Q3 2025, up 0.7% YoY from $2,082M Q3 2024, organic growth 2.7%, adjusted for divestitures and currency
- Operating margin 80.6% Q3 2025 vs 13.2% Q3 2024, driven largely by $1.5B gain on sale of Purification and Filtration business
- Best performing segment Health Information Systems: sales up 5.9% Q3 YoY, operating margin 38.8% vs 32.2% YoY
- Weakest segment Purification and Filtration with sales down (28.7)% Q3 YoY due to divestiture completion in September 2025
- Cash and equivalents $1,642M Sept 30, 2025 vs $762M Dec 31, 2024; $4B proceeds from divestiture boosted cash despite $2.9B debt repayments
- Management highlights tariff-related cost pressures, ongoing stand-alone cost investments, but expects growth from core segments and improved operating leverage
Risk Factors
- No new or changed risk factors since 2024 10-K
- Continued risks from supply chain disruptions impacting production timelines
- Regulatory compliance risks due to evolving industry standards and environmental laws
- Market competition intensifying with new entrants in core product segments
- Liquidity risk from debt maturities upcoming in next 12 months totaling $120M
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Solventum quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.